Since inhibition of PARP1 activity is a well-known strategy for cancer treatment, our data suggest that high-affinity binding compounds targeting the PARP1 C-terminus, which disrupt the interaction with PARP1 C-terminal interactors, might serve as an alternative or supplement for PARP inhibitors in cancer treatment. Here, PARP1 is linked to cancer.